Atrial pocket closures for prosthetic heart valves

Information

  • Patent Grant
  • 11464629
  • Patent Number
    11,464,629
  • Date Filed
    Friday, February 21, 2020
    4 years ago
  • Date Issued
    Tuesday, October 11, 2022
    a year ago
Abstract
A prosthetic heart valve can include an outer frame coupled to an inner frame such that the outer frame can be moved between a first position and a second position in which the outer frame is inverted relative to the inner frame. The inner frame and the outer frame define between them an annular space, and a pocket closure can bound the annular space to form a pocket in which thrombus can form and be retained. The pocket closure can include a stretchable pocket covering that can move from a first position in which the pocket covering has a first length when the outer frame is in the first position relative to the inner frame and a second position in which the pocket covering has a second length greater than the first length when the outer frame is in the second position relative to the inner frame.
Description
BACKGROUND

Prosthetic heart valves, including those for insertion into atrioventricular valves (tricuspid and mitral valves) are susceptible to various problems, including problems with insufficient articulation and sealing of the valve within the native valve annulus, pulmonary edema due to poor atrial drainage, perivalvular leaking around the install prosthetic valve, lack of a good fit for the prosthetic valve within the native valve annulus, atrial tissue erosion, excess wear on the Nitinol structures, interference with the aorta at the anterior side of the mitral annulus, lack of customization, and thrombus formation, to name a few. Accordingly, there is a need for a prosthetic heart valve that can address some or all of these problems.


Moreover, there are a variety of different delivery approaches for delivering and deploying a prosthetic heart valve into atrioventricular valves and depending on the delivery approach the desired features and structure of a prosthetic heart valve can vary. For example, in transvascular delivery of a prosthetic heart valve it is desirable to have a prosthetic heart valve that can have an expanded configuration for implantation within the heart and a collapsed or compressed configuration that has a sufficiently small outer perimeter or diameter to allow the prosthetic heart valve to be placed in a relatively small delivery catheter or sheath. In such embodiments of a prosthetic heart valve, it is also desirable for features of the prosthetic heart valve, such as those described above, to be maintained.


SUMMARY

In some embodiments, a prosthetic heart valve can include an outer frame coupled to an inner frame such that the outer frame can be moved between a first position relative to the inner frame and a second position relative to the inner frame in which the outer frame is inverted relative to the inner frame. The inner frame and the outer frame define between them an annular space. In some embodiments, a pocket closure bounds the annular space to form a pocket in which thrombus can form and be retained. The pocket closure can include a stretchable pocket covering that can move from a first position in which the pocket covering has a first length when the outer frame is in the first position relative to the inner frame and a second position in which the pocket covering has a second length greater than the first length when the outer frame is in the second position relative to the inner frame.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A and 1B are a schematic perspective view and a side cross-sectional view, respectively, of a prosthetic heart valve, according to an embodiment.



FIG. 2A is a schematic perspective view, of an inner valve assembly of the prosthetic heart valve of FIGS. 1A and 1B.



FIGS. 2B and 2C are schematic top views of the inner valve of FIG. 2A, shown in a first configuration and a second configuration, respectively.



FIGS. 3-5 are front, bottom, and top views, respectively, of a prosthetic heart valve according to another embodiment.



FIGS. 6A and 6B are schematic illustrations of a portion of a prosthetic heart valve, according to an embodiment, shown in a first configuration and a second configuration, respectively.



FIGS. 6C and 6D are schematic illustrations of the portion of the prosthetic heart valve of FIGS. 6A and 6B, respectively, shown disposed within a delivery sheath.



FIGS. 7A and 7B are schematic illustrations of the portion of a prosthetic heart valve of FIGS. 6A and 6B, shown in the first configuration and the second configuration, respectively.



FIG. 8A is a front view of a prosthetic heart valve according to another embodiment, shown in a first configuration.



FIG. 8B is a front view of the prosthetic heart valve of FIG. 8A, shown in a second configuration.



FIG. 9A is a front view of a prosthetic heart valve according to another embodiment, shown in a first configuration.



FIG. 9B is an enlarged view of encircled portion A of the prosthetic heart valve of FIG. 9A.



FIG. 9C is a front view of the prosthetic heart valve of FIG. 9A, shown in a second configuration.



FIG. 10A is a cross-sectional side view of a prosthetic heart valve, according to another embodiment.



FIG. 10B is an enlarged view of encircled area A in FIG. 10A.



FIG. 10C is a perspective view of the prosthetic heart valve of FIG. 10A.



FIG. 10D is a perspective view of a prosthetic heart valve, according to another embodiment.





DETAILED DESCRIPTION

Prosthetic heart valves are described herein that include an outer frame coupled to an inner frame. The outer frame and the inner frame define between them an annular space, and a pocket closure bounds the annular space to form a pocket in which thrombus can form and be retained. In some embodiments, a prosthetic heart valve includes an outer frame coupled to an inner frame such that the outer frame can be moved between a first position relative to the inner frame and a second position relative to the inner frame in which the outer frame is inverted relative to the inner frame. In such an embodiment, the pocket closure can include a stretchable pocket covering that can move from a first position in which the pocket covering has a first length when the outer frame is in the first position relative to the inner frame and a second position in which the pocket covering has a second length greater than the first length when the outer frame is in the second position relative to the inner frame.


In some embodiments, prosthetic heart valves described herein can be configured to be moved to an inverted configuration for delivery of the prosthetic valve to within a heart of a patient. For example, in some embodiments, a prosthetic valve includes an outer frame that can be inverted relative to an inner frame when the prosthetic valve is in a biased expanded configuration. The prosthetic mitral valve can be formed with, for example, a shape-memory material. After inverting the outer frame, the prosthetic valve can be inserted into a lumen of a delivery sheath such that the prosthetic valve is moved to a collapsed configuration.


The delivery sheath can be used to deliver an inverted prosthetic valve as described herein to within a patient's heart using a variety of different delivery approaches for delivering a prosthetic heart valve (e.g., prosthetic mitral valve) where the inverted prosthetic valve would enter the heart through the atrium of the heart. For example, the prosthetic valves described herein can be delivered using a transfemoral delivery approach as described in International Application No. PCT/US15/14572 (the '572 PCT application) incorporated by reference above or via a transatrial approach, such as described in U.S. Provisional Patent Application Ser. No. 62/220,704, entitled “Apparatus and Methods for Transatrial Delivery of Prosthetic Mitral Valve,” filed Sep. 18, 2015 (“the '704 provisional application”), and described in U.S. patent application Ser. No. 15/265,221 filed Sep. 14, 2016 (the '221 application”), the entire disclosures of which are incorporated herein by reference in their entirety. In another example, an inverted valve as described herein could be delivered via a transjugular approach, via the right atrium and through the atrial septum and into the left atrium, as described in the '221 application. The prosthetic valves described herein can also be delivered apically if desired. After the delivery sheath has been disposed within the left atrium of the heart, the prosthetic mitral valve is moved distally out of the delivery sheath such that the inverted outer frame reverts and the prosthetic valve assumes its biased expanded configuration. The prosthetic mitral valve can then be positioned within a mitral annulus of the heart.


A schematic representation of a prosthetic heart valve 100 is shown in FIGS. 1A and 1B. Prosthetic heart valve 100 (also referred to as “prosthetic valve” or “valve”) is designed to replace a damaged or diseased native heart valve such as a mitral valve. Valve 100 includes an outer frame assembly 110 and an inner valve assembly 140 that is coupled to the outer frame assembly.


Although not separately shown in the schematic illustration of outer frame assembly 110 in FIGS. 1A and 1B, outer fame assembly 110 may be formed of an outer frame 120, and can be covered on all or a portion of its outer face with an outer covering (not shown), and covered on all or a portion of its inner face by an inner covering (not shown). An embodiment of a prosthetic valve showing the inner and outer coverings is described below with respect to FIGS. 3-5. In some embodiments, the outer frame assembly 110 can include a covering on only an outer face or only an inner face of the outer frame 120. In some embodiments, there can be more than one layer of covering on the inner face and/or the outer face of the outer frame 120. The inner and outer coverings of the outer frame assembly 110 can completely cover the inner face and/or outer face of the outer frame 120 or can partially cover the inner face and/or the outer face of the outer frame 120. In some embodiments, the outer frame assembly 110 may not include a covering on the inner face or the outer face of the outer frame 120. For example, in some embodiments, the outer frame assembly 110 can include no material or covering on an inner face of the outer frame 120 and two layers or coverings disposed on an outer face of the outer frame 120. In such an embodiment, a first layer or covering can be, for example, a tissue that fully covers the outer face of the outer frame 120 and the outermost layer or covering can be a thin polyester that covers only a portion of the outer frame 120. For example, the outermost covering can cover one or two rows of cells of a cuff portion of the outer frame 120.


Outer frame 120 can provide several functions for prosthetic heart valve 100, including serving as the primary structure, as an anchoring mechanism and/or an attachment point for a separate anchoring mechanism to anchor the valve to the native heart valve apparatus, a support to carry inner valve assembly 140, and/or a seal to inhibit paravalvular leakage between prosthetic heart valve 100 and the native heart valve apparatus.


Outer frame 120 is preferably formed so that it can be deformed (compressed and/or expanded) and, when released, return to its original (undeformed) shape. To achieve this, outer frame 120 is preferably formed of materials, such as metals or plastics, that have shape memory properties. With regards to metals, Nitinol® has been found to be especially useful since it can be processed to be austenitic, martensitic or super elastic. Other shape memory alloys, such as Cu—Zn—Al—Ni alloys, and Cu—Al—Ni alloys, may be used.


Outer frame 120 is preferably formed from a laser cut, thin-walled tube of Nitinol®. The laser cuts form regular cutouts in the thin Nitinol® tube. The tube can be expanded radially, placed on a mold or mandrel of the desired shape, heated to the martensitic temperature, and quenched. The treatment of the frame in this manner will form an open lattice frame structure, and may have a flared end or cuff at the atrium end portion 116 of outer frame 120. Outer frame 120 thus has shape memory properties and will readily revert to the memory shape at the calibrated temperature. Alternatively, outer frame 120 may be constructed from braided wire or other suitable material.


Inner valve assembly 140 is shown schematically in more detail in FIGS. 2A-2C. Inner valve assembly 140 can include an inner frame 150, an outer covering 160, and leaflets 170. In the simplified form shown schematically in FIG. 2A, inner frame 150 includes six axial posts or frame members that support outer covering 160 and leaflets 170. Leaflets 170 are attached along three of the posts, shown as commissure posts 152 in FIG. 2A, and outer covering 160 is attached to the other three posts, 154 in FIG. 2A, and optionally to commissure posts 152. The outer covering 160 can be attached to an inner face of the inner frame 150 or to an outer face of the inner frame 150. As shown schematically in FIG. 2A, each of outer covering 160 and leaflets 170 are formed of approximately rectangular sheets of material, which are joined together at their upper, or atrium end. The lower, ventricle end of outer covering 160 may be joined to the inner covering (not shown) of outer frame assembly 110 (not shown in FIG. 2A), and the lower, ventricle end of leaflets 170 may form free edges, though coupled to the lower ends of commissure posts 152. In some embodiments, the covering 160 and leaflets 170 can be formed from a single rectangular sheet of material, then folded over and trimmed to the shape of the inner frame, staying connected at the top of the inner frame where the material is folded over. In some embodiments, the covering 160 and/or the leaflets 170 can be formed from material having a shape other than rectangular, such as from a semi-circular piece of material, or can be laser cut to the shape of the inner frame.


As shown in FIGS. 2B and 2C, leaflets 170 are movable between a first or open configuration (FIG. 2B), and a second or closed configuration (FIG. 2C) in which the leaflets 170 coapt, or meet in sealing abutment.


At the lower, or ventricle end, leaflets 170 may have a smaller outer perimeter than outer covering 160. Thus, the free lower edges of the leaflets 170, between commissure posts 152 (each portion of leaflets 170 between adjacent commissure posts being referred to as a “belly” of leaflets 170) are spaced radially from the lower edge of outer covering 160. This radial spacing facilitates movement of the leaflets from the open position in FIG. 2B to the closed position in FIG. 2C, as the counter flow of blood from the ventricle to the atrium during systole can catch the free edges of the bellies and push the leaflets closed.


The outer covering and the inner covering of outer frame assembly 110, outer covering 160 and leaflets 170 may be formed of any suitable material, or combination of materials. In some embodiments, the outer covering and the inner covering of outer frame assembly 110, outer covering 160 and leaflets 170 may be formed of a tissue. In some embodiments, the tissue is optionally a biological tissue, such as a chemically stabilized tissue from a heart valve of an animal, such as a pig, or pericardial tissue of an animal, such as cow (bovine pericardium) or sheep (ovine pericardium) or pig (porcine pericardium) or horse (equine pericardium). Examples of suitable tissue include that used in the products Duraguard®, Peri-Guard®, and Vascu-Guard®, all products currently used in surgical procedures, and which are marketed as being harvested generally from cattle less than 30 months old. Alternatively, valve leaflets 170 may optionally be made from pericardial tissue or small intestine submucosal tissue.


Synthetic materials, such as polyurethane or polytetrafluoroethylene, may also be used for valve leaflets 170. Where a thin, durable synthetic material is contemplated, e.g. for the outer covering or the inner covering of outer frame assembly 110, synthetic polymer materials such as, for example, expanded polytetrafluoroethylene or polyester may optionally be used. Other suitable materials may optionally include thermoplastic polycarbonate urethane, polyether urethane, segmented polyether urethane, silicone polyether urethane, silicone-polycarbonate urethane, and ultra-high molecular weight polyethylene. Additional biocompatible polymers may optionally include polyolefins, elastomers, polyethylene-glycols, polyethersulphones, polysulphones, polyvinylpyrrolidones, polyvinylchlorides, other fluoropolymers, silicone polyesters, siloxane polymers and/or oligomers, and/or polylactones, and block co-polymers using the same.


In another embodiment, valve leaflets 170 may optionally have a surface that has been treated with (or reacted with) an anti-coagulant, such as, without limitation, immobilized heparin. Such currently available heparinized polymers are known and available to a person of ordinary skill in the art.


As shown in FIGS. 1A, 1B, and 2A, inner valve assembly 140 may be substantially cylindrical, and outer frame assembly 110 may be tapered, extending from a smaller diameter (slightly larger than the outer diameter of inner valve assembly 140) at a lower, ventricle portion 112 (where it is coupled to inner valve assembly 140) to a larger diameter, atrium portion 116, with an intermediate diameter, annulus portion 114 between the atrium and ventricle portions, 112 and 116, respectively.


A tapered annular space or pocket 185 (also referred to herein as “atrial pocket”) is thus formed between the outer surface of inner valve assembly 140 and the inner surface of outer frame assembly 110, open to the atrium end of valve assembly 100. When valve assembly 100 is disposed in the annulus of a native heart valve, blood from the atrium can move in and out of pocket 185. The blood can clot, forming thrombus. To enhance clotting, ingrowth of tissue into the surfaces of valve 100, and produce other benefits, the pocket can be covered, or enclosed, by a pocket closure 180 (also referred to as an “atrial pocket closure”).


Pocket closure 180 can be formed at least in part of any suitable material that is sufficiently porous to allow blood, including particularly red blood cells, to enter pocket 185, but is not so porous as to allow undesirably large thrombi to leave the pocket 185. For example, pocket closure 180 may be formed at least in part from a woven or knit polyester fabric with apertures less than 160μ, and preferably between 90μ and 120μ. In some embodiments, the pocket closure 180 can be formed at least in part from a braided Nitinol material that has a desired porosity. In some embodiments, the pocket closure 180 can be formed at least in part from a braided tubular Nitinol material. It is not necessary for the entirety of pocket closure 180 to be formed of the same material, with the same porosity. For example, some portions of pocket closure 180 may be formed of a less porous, or blood impermeable, material and other portions formed of material of the porosity range noted above. It is also contemplated that a portion of the outer frame assembly 110 or the inner valve assembly 140 may be formed with an aperture that communicates with pocket 180, covered by a closure formed of material having the desired porosity, thus providing another path by which blood may enter, but thrombi are prevented from leaving, atrial pocket 185.


The outer surface of inner valve assembly 110, and/or the inner surface of outer frame assembly 140, need not by circular in cross-section as shown schematically in FIGS. 1A and 1B, but may be of non-constant radius at a given location along the central axis of valve 100. Thus, pocket 185 may not be of constant cross-section, and may not be continuous, but rather may be formed in two or more fluidically isolated, partially annular volumes. Similarly, pocket closure 180 need not be shaped as a ring with constant width as shown schematically in FIGS. 1A and 1B, but rather can be a continuous ring of varying with, a more complicated continuous shape, or may be formed in multiple, discrete sections. In some embodiments, the pocket closure 180 can be formed as a tubular member defining an interior region.


Pocket closure 180 serves to trap and/or slow the flow of blood within pocket 185, which can increase formation and retention of thrombus in pocket 185. It also promotes active in-growth of native tissue into the several coverings of prosthetic heart valve 100, further stabilizing valve 100 in the native heart valve. The material forming the outer covering of inner valve assembly 140 can also be hardened or stiffened, providing better support for leaflets 170. Also, a mass of thrombus filling pocket 185 can serve as potting for inner valve assembly 140, further stabilizing the valve assembly. Greater stability for inner valve assembly 140 can provide more reliable coaption of valve leaflets 170, and thus more effective performance. The mass of thrombus can also stabilize the outer frame assembly 110 after it has been installed in, and flexibly conformed to, the native valve apparatus. This can provide a more effective seal between prosthetic heart valve 100 and the native valve apparatus, and reduce perivalvular leakage.



FIGS. 3-5 are front, bottom, and top views, respectively, of a prosthetic heart valve 200 according to an embodiment. Prosthetic heart valve 200 (also referred to herein as “valve” or “prosthetic valve”) is designed to replace a damaged or diseased native heart valve such as a mitral valve. Valve 200 includes an outer frame assembly 210 and an inner valve assembly 240 coupled to the outer frame assembly 210.


As shown, outer frame assembly 210 includes an outer frame 220, covered on all or a portion of its outer face with an outer covering 230, and covered on all or a portion of its inner face by an inner covering 232. Outer frame 220 can provide several functions for prosthetic heart valve 200, including serving as the primary structure, as an anchoring mechanism and/or an attachment point for a separate anchoring mechanism to anchor the valve to the native heart valve apparatus, a support to carry inner valve assembly 240, and/or a seal to inhibit paravalvular leakage between prosthetic heart valve 200 and the native heart valve apparatus.


Outer frame 220 has a biased expanded configuration and can be manipulated and/or deformed (e.g., compressed and/or constrained) and, when released, return to its original unconstrained shape. To achieve this, outer frame 220 can be formed of materials, such as metals or plastics, that have shape memory properties. With regards to metals, Nitinol® has been found to be especially useful since it can be processed to be austenitic, martensitic or super elastic. Other shape memory alloys, such as Cu—Zn—Al—Ni alloys, and Cu—Al—Ni alloys, may also be used.


As best shown in FIG. 3, outer frame assembly 210 has an upper end (e.g., at the atrium portion 216), a lower end (e.g., at the ventricle portion 212), and a medial portion (e.g., at the annulus portion 214) therebetween. The upper end or atrium portion 216 (also referred to as “free end portion” or “open end portion”) defines an open end portion of the outer frame assembly 210. The medial or annulus portion 214 of the outer frame assembly 210 has a perimeter that is configured (e.g., sized, shaped) to fit into an annulus of a native atrioventricular valve. The upper end of the outer frame assembly 210 has a perimeter that is larger than the perimeter of the medial portion. In some embodiments, the perimeter of the upper end of the outer frame assembly 210 has a perimeter that is substantially larger than the perimeter of the medial portion. As shown best in FIG. 5, the upper end and the medial portion of the outer frame assembly 210 has a D-shaped cross-section. In this manner, the outer frame assembly 210 promotes a suitable fit into the annulus of the native atrioventricular valve.


Inner valve assembly 240 includes an inner frame 250, an outer covering 260, and leaflets 270. As shown, the inner valve assembly 240 includes an upper portion having a periphery formed with multiple arches. The inner frame 250 includes six axial posts or frame members that support outer covering 260 and leaflets 270. Leaflets 270 are attached along three of the posts, shown as commissure posts 252 (best illustrated in FIG. 4), and outer covering 260 is attached to the other three posts, 254 (best illustrated in FIG. 4), and optionally to commissure posts 252. Each of outer covering 260 and leaflets 270 can be formed as described above for outer covering 160 and leaflets 170. For example, each of outer covering 260 and leaflets 270 can be formed of approximately rectangular sheets of material, which are joined together at their upper, or atrium end. The lower, ventricle end of outer covering 260 may be joined to inner covering 232 of outer frame assembly 210, and the lower, ventricle end of leaflets 270 may form free edges 275, though coupled to the lower ends of commissure posts 252.


Although inner valve assembly 240 is shown as having three leaflets, in other embodiments, an inner valve assembly can include any suitable number of leaflets. The leaflets 270 are movable between an open configuration and a closed configuration in which the leaflets 270 coapt, or meet in a sealing abutment.


Outer covering 230 of the outer frame assembly 210 and inner covering 232 of outer frame assembly 210, outer covering 260 of the inner valve assembly 240 and leaflets 270 of the inner valve assembly 240 may be formed of any suitable material, or combination of materials, such as those discussed above for valve 100. In this embodiment, the inner covering 232 of the outer frame assembly 210, the outer covering 260 of the inner valve assembly 240, and the leaflets 270 of the inner valve assembly 240 are formed, at least in part, of porcine pericardium. Moreover, in this embodiment, the outer covering 230 of the outer frame assembly 210 is formed, at least in part, of polyester.


Prosthetic valve 200 also defines a tapered annular space or pocket (not shown) formed between the outer surface of inner valve assembly 240 and the inner surface of outer frame assembly 210, open to the atrium end of valve assembly 200. As shown, a pocket closure or covering 280 (the pocket being disposed below pocket closure 280 in the top view of FIG. 5) is coupled along the periphery of the upper end of the inner valve assembly 240 and also to the outer valve assembly 210. In some embodiments, the pocket closure 280, or a portion thereof, can be coupled along any suitable portion of the inner valve assembly 240.


As discussed above, pocket closure 280 can be formed at least in part of any suitable material that is sufficiently porous to allow blood, including particularly red blood cells, to enter the pocket, but is not so porous as to allow undesirably large thrombi to leave the pocket. In this embodiment, pocket closure 280 is formed entirely of knit polyester (i.e., PET warp knit fabric) having apertures of about 90-120 microns. In some embodiments, a pocket closure can include apertures less than about 160 microns.


As previously described, in some embodiments, a prosthetic heart valve, such as a prosthetic mitral valve, can be configured to be moved to an inverted configuration for delivery of the prosthetic valve to within a heart of a patient. For example, the outer frame can be moved or inverted relative to the inner frame of the valve. After inverting the outer frame, the prosthetic valve can be inserted into a lumen of a delivery sheath such that the prosthetic valve is moved to a collapsed configuration for delivery of the valve o the heart. FIGS. 6A-6D and FIGS. 7A and 7B illustrate schematically an embodiment of a prosthetic valve that can be moved between a biased expanded configuration for use and an inverted configuration for delivery to a heart.



FIGS. 6A and 6B are schematic illustrations of a portion of a prosthetic heart valve 300, according to an embodiment, shown in a first configuration and a second configuration respectively, and FIGS. 6C and 6D illustrate the portions of the prosthetic heart valve 300 of FIGS. 6A and 6B, respectively, shown disposed within a lumen of a delivery sheath 326. FIGS. 7A and 7B illustrate a portion of the prosthetic heart valve 300 of FIGS. 6A and 6B, respectively, and show length dimensions for the prosthetic heart valve in each of the first configuration and the second configuration. The prosthetic heart valve 300 (also referred to herein as “prosthetic valve” or “valve”) can be, for example, a prosthetic mitral valve. The valve 300 includes an outer frame 320 and an inner frame 350. The outer frame 320 and the inner frame 350 are each formed as a tubular structure. The outer frame 320 and the inner frame 350 can be coupled together at multiple coupling joints 346 disposed about a perimeter of the inner frame 350 and a perimeter of the outer frame 320 as described in more detail below. The valve 300 can also include other features, such as those described above with respect to FIGS. 1-5. For example, the valve 300 can include an outer frame assembly, including the outer frame 320, and an inner valve assembly that includes the inner frame 350, that can be formed or configured the same as or similar to the outer frame assemblies and inner valve assemblies described above with respect to FIGS. 1-5. For illustration purposes, only the inner frame 350 and the outer frame 320 are discussed with respect to FIGS. 6A-7B. The various characteristics and features of valve 300 described with respect to FIGS. 6A-7B can apply to any of the prosthetic valves described here.


The outer frame 320 is configured to have a biased expanded or undeformed shape and can be manipulated and/or deformed (e.g., compressed or constrained) and, when released, return to its original (expanded or undeformed) shape. For example, the outer frame 320 can be formed of materials, such as metals or plastics, that have shape memory properties. With regards to metals, Nitinol® has been found to be especially useful since it can be processed to be austenitic, martensitic or super elastic. Other shape memory alloys, such as Cu—Zn—Al—Ni alloys, and Cu—Al—Ni alloys, may also be used. The inner frame 350 can be formed from a laser-cut tube of Nitinol®. The inner frame 350 can also have a biased expanded or undeformed shape and can be manipulated and/or deformed (e.g., compressed and/or constrained) and, when released, return to its original (expanded or undeformed) shape. Further details regarding the inner frame 350 and the outer frame 320 are described below and with respect to valve 200 and FIGS. 3-5.


The valve 300 can be delivered and deployed within a left atrium of a heart using a variety of different delivery approaches including, for example, a transfemoral delivery approach, as described in the '572 PCT application, or a transatrial approach, as described in the '704 provisional application and the '221 application, or a transjugular approach as described, for example, in the '221 application. As described above, in some situations, such as when delivering a prosthetic valve to the heart via a transfemoral, transjugular or transatrial approach, because of the smaller size of the lumen of the delivery sheath, the size of the prosthetic valve during delivery should be sized accordingly. Thus, it is desirable to have a prosthetic valve that can be reconfigured between a biased expanded configuration for implantation in the heart (e.g., within a native mitral annulus) and a delivery configuration that has a smaller outer perimeter or profile to allow for delivery within the lumen of the delivery sheath. The prosthetic valve 300 and the embodiments of a prosthetic valve described herein can be constructed and formed to achieve these desired functions and characteristics.


More specifically, the valve 300 can have a biased expanded configuration (as shown in FIGS. 6A and 7A), an inverted configuration (as shown in FIGS. 6B and 7B), and a compressed or collapsed configuration (as shown in FIGS. 6C and 6D). The expanded configuration allows the valve 300 to function when implanted within the heart. The valve 300 can be moved to the inverted configuration and the compressed or collapsed configuration for delivery of the valve 300 to the heart of a patient.


To enable the valve 300 to be moved to the inverted configuration, the outer frame 320 can be coupled to the inner frame 350 in such a manner to allow the outer frame 320 to move relative to the inner frame 350. More specifically, the coupling joints 346 can couple the outer frame 320 to the inner frame 350 in such a manner to allow the outer frame 320 to be moved relative to the inner frame 350. For example, in some embodiments, the coupling joints 346 can be configured to allow the outer frame 320 to rotate about the coupling joint 346 relative to the inner frame 350. In some embodiments, coupling joints can provide a pivotal coupling between the outer frame 320 and the inner frame 350. In some embodiments, the coupling joints can provide a flexible attachment between the outer frame 320 and the inner frame 350. The coupling joints 346 can be a variety of different types and configurations as described herein with reference to the various embodiments of a prosthetic valve. For example, the coupling joints 146 can include a living hinge, a flexible member, sutures, a suture wrapped through an opening, a pin or tab inserted through an opening or any combinations thereof.


To move the valve 300 from the expanded configuration (FIG. 6A) to the inverted configuration (FIG. 6B), the outer frame 320 is moved to a prolapsed or inverted configuration relative to the inner frame 350, as shown in FIGS. 6B, 6D and 7B, by moving (e.g., rotating, pivoting, flexing) the outer frame 320 about the coupling joints 346. The elastic or superelastic structure of outer frame 320 of valve 300 also allows the outer frame 320 to be moved to, and disposed in, the prolapsed or inverted configuration relative to the inner frame 350. To move the outer frame 320 to the inverted configuration relative to the inner frame 350, the outer frame 320 is folded or inverted distally (to the right in FIG. 6B) relative to the inner frame 350 via the coupling joints 346. As shown in FIGS. 6A and 7A, the outer frame 320 is in a first position relative to the inner frame 350 prior to being inverted in which an open or free end portion 316 (also referred to the atrium portion 316 of the outer frame 320) is disposed proximally or to the left of the coupling joints 346 and in the same direction as a free end portion 347 (also referred to as a second end portion of the inner frame) of the inner frame 350. When the outer frame 320 is moved to an inverted configuration (i.e., second positon relative to the inner frame 350), the free end portion 316 is disposed distally of the coupling joints 346 (or to the right in FIGS. 6B and 7B) and in an opposite direction as the free end portion 347 of the inner frame 350. Said another way, when the valve 300 is in a biased expanded configuration (e.g., FIG. 6A), the coupling joints 346 are disposed between a first end portion 344 (also referred to as a tether coupling portion) of the inner frame 350 and the free end portion 316 of the outer frame 320. When the valve 300 is in the inverted configuration (e.g., FIG. 6B) (i.e., the outer frame 320 has been moved to an inverted configuration or position), the coupling joints 346 are disposed between the free end portion or second end portion 347 of the inner frame 350 and the free end portion 316 of the outer frame 320.


When in the inverted configuration, an overall length of the valve 300 is increased, but a length of the inner frame 350 and a length of the outer frame 320 remains the same (or substantially the same). For example, as shown in FIGS. 7A and 7B an overall length L1 of the valve 300 in the biased expanded configuration (prior to being inverted as shown in FIG. 7A) is less than the overall length L2 of the valve 300 when in the inverted configuration (FIG. 7B). A length Li of the inner frame 350 and a length Lo of the outer frame 320 is substantially the same (or the same) when the valve 300 is in both the biased expanded configuration and the inverted configuration. In addition, in some instances, depending on the specific configuration of the outer frame, an overall outer perimeter or outer diameter of the valve 300 can be smaller when the valve 300 is in the inverted configuration.


With the valve 300 in the inverted configuration, the valve 300 can be placed within a lumen of the delivery sheath 326 for delivery of the valve 300 to the left atrium of the heart, as shown in FIG. 6D. When placed within the lumen of the delivery sheath 326, the valve 300 is moved to the collapsed or compressed configuration in which the outer diameter or outer perimeter of the valve 300 is reduced. Because the valve 300 is in the inverted configuration, the valve 300 is able to be placed within a smaller delivery sheath 326 than would otherwise be possible. For example, for comparison purposes, FIG. 6C illustrates the valve 300 placed within a lumen of a delivery sheath 326′ where the valve 300 has not been moved to an inverted configuration prior to being disposed within the delivery sheath 326′. As shown in FIG. 6C, an outer diameter of the valve 300 is reduced, but not to as small of a diameter as for the valve 100 when placed in a delivery sheath 326 when in the inverted configuration. Thus, in FIG. 6C, the valve 300 has an overall outer perimeter or outer diameter D1 and in FIG. 6D, the valve 300 has an overall outer perimeter or outer diameter D2, which is less than D1.


Thus, by disposing the outer frame 320 in the inverted configuration, the valve 300 can be collapsed into a smaller overall diameter, i.e. placed in a smaller diameter delivery sheath 326, than would be possible if the valve 300 were merely collapsed radially. This is because when the valve is in the biased expanded configuration, the inner frame 350 is nested within an interior of the outer frame 320, and thus the outer frame 320 must be collapsed around the inner frame 350. In some embodiments, the inner frame 350 and the outer frame are disposed concentrically. Whereas in the inverted configuration, the inner frame 350 and the outer frame 320 are arranged axially with respect to each other (i.e., the inner frame is not nested within the outer frame 350), such that the outer frame 320 can be collapsed without needing to accommodate all of the structure of the inner frame 350 inside it. In other words, with the inner frame 350 disposed mostly inside or nested within the outer frame 320, the layers or bulk of the frame structures cannot be compressed to as small a diameter. In addition, if the frames are nested, the structure is less flexible, and therefore, more force is needed to bend the valve, e.g. to pass through tortuous vasculature or to make tight turn in the left atrium after passing through the atrial septum to be properly oriented for insertion into the mitral valve annulus.



FIGS. 8A and 8B illustrate another embodiment of a prosthetic heart valve that can be delivered and deployed within a left atrium of a heart using a variety of different delivery approaches and which can be moved between an expanded configuration and an inverted configuration as described above for valve 300. The prosthetic heart valve 400 (also referred to herein as “prosthetic valve” or “valve”) can be, for example, a prosthetic mitral valve. The valve 400 includes an outer frame assembly including an outer frame 420 and an inner valve assembly including an inner frame 450. The outer frame 420 and the inner frame 450 are each formed as a tubular structure. The valve 400 can also include other features, such as those described above with respect to FIGS. 1A-7D. For illustration purposes, only the inner frame 450 and the outer frame 420 are discussed with respect to FIGS. 8A-8B. It should be understood that the various characteristics and features of the valves described above with respect to FIGS. 1A-7D can apply to valve 400.


The outer frame 420 and the inner frame 450 can be coupled together at multiple coupling joints 446 disposed about a perimeter of the inner frame 450 and a perimeter of the outer frame 420 as described above for valve 300. The coupling joints 446 can allow the outer frame 420 to be moved relative to the inner frame 450 as described above for valve 300. For example, the outer frame 420 can be moved between a first position (FIG. 8A) relative to the inner frame 450 to a second position (FIG. 8B) relative to the inner frame 450. In the first position, an open free end portion 416 of the outer frame 420 is disposed in the same direction as an open free end portion 447 of the inner frame 450 (see FIG. 8A). In the second position, the outer frame 420 is inverted relative to the inner frame 450 such that the free end portion 416 of the outer frame 420 is now disposed in an opposite direction as the free end portion 447 of the inner frame 450 (see FIG. 8B).


As described above for valves 100 and 200, a tapered annular space or pocket 485 (also referred to as “atrial pocket”) is formed between an outer surface of the inner valve assembly and an inner surface of the outer frame assembly, open to an atrium end of valve 400. When valve 400 is disposed in the annulus of a native heart valve, blood from the atrium can move in and out of pocket 485. The blood can clot, forming thrombus. To enhance clotting, ingrowth of tissue into the surfaces of valve 400, and produce other benefits, the pocket 485 can be covered, or enclosed, by a pocket closure 480 (also referred to as an “atrial pocket closure”). The pocket closure 480 is coupled about a perimeter of the inner frame 450 and a perimeter of the outer frame 420 so as to close-out the pocket 485 at the atrial end of the valve 400. As shown in FIGS. 8A and 8B the pocket closure 480 is coupled to the inner frame 450 at coupling portion 482 and to outer frame 420 at coupling portion 483. The pocket closure 480 can be formed of one continuous segment or portion of material or can be formed with two or more portions or segments that are coupled together. For example, in some embodiments, the pocket closure 480 can be formed of three portions or segments that are sewn together with sutures or another suitable coupling method.


As described above, pocket closure 480 can be formed at least in part of any suitable material that is sufficiently porous to allow blood, including particularly red blood cells, to enter the pocket 485, but is not so porous as to allow undesirably large thrombi to leave the pocket 485. For example, pocket closure 480 may be formed at least in part from a material with apertures less than 160μ, and preferably between 90μ and 120μ. In this embodiment, the pocket closure 480 can be formed at least in part from a braided Nitinol material (or a braided tubular Nitinol material) that has the desired porosity. The braided Nitinol material also provides a desired stretchability, flexibility or deformability to accommodate movement of the outer frame 420 between the first positon relative to the inner frame 450 and the second inverted position relative to the inner frame 450. For example, the braided Nitinol material can have shape memory properties that allow the pocket closure 480 to be deformed and/or stretched and then revert back to an original shape or configuration when released.


As shown in FIG. 8A, when the outer frame 420 is in the first position relative to the inner frame 450, the pocket closure 480 is disposed in a first configuration. As shown in FIG. 8B, when the outer frame 420 is in the second position (i.e., inverted) relative to the inner frame 450, the pocket closure 480 is disposed in a second configuration. More specifically, when the outer frame 420 is moved to the second position in which the outer frame 420 is inverted relative to the inner frame 420, the material and structure of the pocket closure 480 enables the pocket closure 480 to stretch with the outer frame 420 as shown in FIG. 8B. In other words, as shown in FIG. 8B, the pocket closure 480 is stretched or elongated between where it is coupled to the inner frame (i.e., coupling portion 482) and where it is coupled to the outer frame (i.e., coupling portion 483) to a length greater than when the outer frame 420 is in the first positon as shown in FIG. 8A. When the outer frame 420 is moved back to the first position relative to the inner frame 450, the pocket closure 480 can assume its first configuration as shown in FIG. 8A.



FIGS. 9A and 9B illustrate another embodiment of a prosthetic heart valve that includes a pocket closure that can accommodate the valve being moved between an expanded configuration and an inverted configuration for delivery and deployment of the valve within a left atrium of a heart. The prosthetic heart valve 500 (also referred to herein as “prosthetic valve” or “valve”) can be, for example, a prosthetic mitral valve. The valve 500 includes an outer valve assembly including an outer frame 520 and an inner valve assembly including an inner frame 550. The outer frame 520 and the inner frame 550 are each formed as a tubular structure. The valve 500 can also include other features, such as those described above with respect to FIGS. 1A-7D. For illustration purposes, only the inner frame 550 and the outer frame 520 are discussed with respect to FIGS. 8A-8B. It should be understood that the various characteristics and features of the valves described above with respect to FIGS. 1A-7D can apply to valve 500.


As with the previous embodiments, the outer frame 520 and the inner frame 550 can be coupled together at multiple coupling joints 546 disposed about a perimeter of the inner frame 550 and a perimeter of the outer frame 520 as described above for valve 300. The coupling joints 546 can allow the outer frame 520 to be moved relative to the inner frame 550 as described above for valve 300. For example, the outer frame 520 can be moved between a first position (FIG. 9A) relative to the inner frame 550 to a second position (FIG. 9B) relative to the inner frame 550. In the first position, an open free end portion 516 of the outer frame 520 is disposed in the same direction as an open free end portion 547 of the inner frame 550 (see FIG. 9A). In the second position, the outer frame 520 is inverted relative to the inner frame 550 such that the free end portion 516 of the outer frame 520 is now disposed in an opposite direction as the free end portion 547 of the inner frame 550 (see FIG. 9B).


As described above for valves 100 and 200, a tapered annular space or pocket 585 (also referred to as “atrial pocket”) is formed between an outer surface of the inner valve assembly and an inner surface of the outer frame assembly, open to an atrium end of valve 500. When valve 500 is disposed in the annulus of a native heart valve, blood from the atrium can move in and out of pocket 585. The blood can clot, forming thrombus. To enhance clotting, ingrowth of tissue into the surfaces of valve 500, and produce other benefits, the pocket 585 can be covered, or enclosed, by a pocket closure 580 (also referred to as an “atrial pocket closure”).


In this embodiment, the pocket closure 580 includes a first portion 584 coupled to a second portion 586. As shown in the detail view of FIG. 9B, the first portion 584 includes a first end coupled to the outer frame 520 at a coupling joint 587, and a second end coupled to the second portion 586 at a coupling joint 588. The second portion 586 has a first end coupled to the first portion 584 at the coupling joint 588 and a second end coupled to the outer frame 520 at a coupling joint 589. Thus, in this embodiment, the pocket closure 580 is coupled only to the outer frame 520. The pocket closure 580 can close-out the pocket at the atrial end of the valve 500. The first portion 584 and the second portion 586 of the pocket closure 580 can each be formed as one continuous segment or portion of material or can be formed with two or more portions or segments that are coupled together with for example, sutures or another suitable coupling method.


As described above, pocket closure 580 can be formed at least in part of any suitable material that is sufficiently porous to allow blood, including particularly red blood cells, to enter the pocket 585, but is not so porous as to allow undesirably large thrombi to leave the pocket 585. For example, pocket closure 580 may be formed at least in part from a material with apertures less than 160μ, and preferably between 90μ and 120μ. In this embodiment, the first portion 584 of pocket closure 580 can be formed at least in part from a woven or knit polyester fabric with apertures less than 160μ, and preferably between 90μ and 120μ. The second portion 586 of pocket closure 580 can be formed with a tubular braided Nitinol material as described above for valve 400 that can provide a desired stretchability or flexibility or deformability to accommodate the outer frame 520 moving between the first positon relative to the inner frame 550 and the second inverted position relative to the inner frame 550.


As shown in FIG. 9A, when the outer frame 520 is in the first position relative to the inner frame 550, the pocket closure 580 is disposed in a first configuration. As shown in FIG. 9B, when the outer frame 520 is in the second position (i.e., inverted) relative to the inner frame 550, the pocket closure 580 is disposed in a second configuration. More specifically, when the outer frame 520 is moved to the second position in which the outer frame 520 is inverted relative to the inner frame 520, the material and structure of the second portion 586 of the pocket closure 580 enables the pocket closure 580 to stretch with the outer frame 520 as shown in FIG. 9B. In other words, as shown in FIG. 9B, the second portion 586 of pocket closure 580 can stretch or elongate between where it is coupled to the first portion 584 of the pocket closure 580 (i.e., coupling joint 588) and where it is coupled to the outer frame 520 (i.e., coupling portion 589) to a length greater than when the outer frame 520 is in the first positon as shown in FIG. 9A. The first portion 584 of pocket closure 580 does not stretch when the outer frame 520 is moved to the second position (i.e., inverted) relative to the inner frame 550. When the outer frame 520 is moved back to the first position relative to the inner frame 550, the pocket closure 580 can assume its first configuration as shown in FIG. 9A.


In some embodiments of a prosthetic heart valve, an additional material layer can be attached to the inner frame in addition to the outer covering described above for previous embodiments (e.g., outer covering 160). The additional material layer can be attached to an inner face or an outer face of the inner frame of the valve. For example, the additional material layer can be attached to an inner face of the inner frame and outside of the leaflets of the valve. In other words, the outer covering can be disposed between the leaflets and the additional material layer, with all three components (leaflets, outer covering and additional material layer) disposed on an inner side of the inner frame of the valve. The additional material layer may be desirable to prevent possible billowing of the belly area of the leaflet. Such billowing can occur, for example, when backpressure that can cause the leaflets to close also applies pressure to the belly area of the leaflets, potentially causing them to bulge out into the pocket area towards the outer frame. The additional material layer can be composed of a variety of different materials. FIGS. 10A-10C illustrate a prosthetic heart valve 600 that includes such a material layer 625. In this embodiment, the material layer 625 is disposed as a cylinder that covers an inner frame 650 from a base 622 of the inner frame 650 to a peak or atrium end 624 of the inner frame 650. As shown in FIGS. 10A and 10B, the valve 600 includes leaflets 670. As shown in FIG. 10C, the cylindrically disposed material layer 625 bridges the peaks 624 of the frame 650. In an alternative embodiment, the material layer can be configured to follow the shape of the inner frame as shown in FIG. 10D. In this embodiment, a valve 600′ includes a material layer 625′ that substantially follows or conforms to the shape of the inner frame 650. In other words, the material layer 625′ spans between frame portions of the inner frame 650. In some embodiments, the material layers 625, 625′ can be, for example, a polyester material.


While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation, and as such, various changes in form and/or detail may be made. Any portion of the apparatus and/or methods described herein may be combined in any suitable combination, unless explicitly expressed otherwise. The embodiments described herein can include various combinations and/or sub-combinations of the functions, components, and/or features of the different embodiments described.


Where methods described above indicate certain events occurring in certain order, the ordering of certain events and/or flow patterns may be modified. Additionally, certain events may be performed concurrently in parallel processes when possible, as well as performed sequentially.

Claims
  • 1. A method of implanting a prosthetic heart valve into a native valve annulus, the method comprising: disposing the prosthetic heart valve within a delivery device in a collapsed delivery condition, the prosthetic heart valve including an inner frame having an open end portion, and an outer frame coupled to the inner frame and having an open end portion, the outer frame being inverted relative to the inner frame when the prosthetic heart valve is in the collapsed delivery condition so that the open end of the outer frame and the open end of the inner frame point in opposite directions;delivering the delivery device to the native valve annulus;ejecting the prosthetic heart valve from the delivery device;transitioning the prosthetic heart valve from the collapsed delivery condition to an expanded condition, the outer frame reverting relative to the inner frame during the transitioning so that the open end of the outer frame and the open end of the inner frame point in a same direction; andpositioning the prosthetic heart valve in the native valve annulus,wherein in the expanded condition of the prosthetic heart valve, an annular space is defined between a portion of the inner frame and a portion of the outer frame, the annular space being open toward the open end portion of the outer frame and the open end portion of the inner frame when the prosthetic heart valve is in the expanded condition,a pocket covering being coupled to the inner frame and coupled to the outer frame such that the annular space is covered by the pocket covering between the open end portion of the inner frame and the open end portion of the outer frame when the prosthetic heart valve is in the expanded condition.
  • 2. The method of claim 1, wherein the pocket covering is coupled to the inner frame and coupled to the outer frame when the prosthetic heart valve is in the collapsed delivery condition.
  • 3. The method of claim 2, wherein the pocket covering is a stretchable pocket covering.
  • 4. The method of claim 3, wherein the stretchable pocket covering has a first length when the prosthetic heart valve is in the collapsed delivery condition, and the stretchable pocket covering transitions to a second length smaller than the first length when the prosthetic heart valve transitions from the collapsed delivery condition to the expanded condition.
  • 5. The method of claim 3, wherein the stretchable pocket covering, the inner frame, and the outer frame collectively define a pocket in which thrombus can form and be retained when the prosthetic heart valve is in the expanded condition and disposed within the native valve annulus of a patient.
  • 6. The method of claim 5, wherein the pocket covering is formed of a material having a porosity that is sufficiently large to allow red blood cells to pass through the pocket closure into the pocket and that is sufficiently small to prevent thrombus formed from the red blood cells to pass through the pocket closure from the pocket.
  • 7. The method of claim 1, wherein the pocket covering is formed of a braided Nitinol material.
  • 8. The method of claim 1, wherein the prosthetic heart valve includes an outer covering disposed on the inner frame, a plurality of prosthetic leaflets disposed within an interior of the inner frame, and a material layer disposed over the outer covering and conforming to the shape of the inner frame, the material layer configured to prevent billowing of a belly area of the leaflets into the annular space.
  • 9. The method of claim 1, wherein the outer frame is coupled to the inner frame at multiple coupling joints, the inner frame including a tether coupling portion opposite the open end portion of the inner frame, the coupling joints being disposed between the open end portion of the outer frame and the tether coupling portion of the inner frame when the prosthetic heart valve is in the expanded condition, the coupling joints being disposed between the open end portion of the inner frame and the open end portion of the outer frame when the prosthetic heart valve is in the collapsed delivery condition.
  • 10. The method of claim 1, wherein the pocket covering has a first portion coupled to a second portion, the first portion being coupled to the outer frame at a first coupling joint, the second portion being coupled to the outer frame at a second coupling joint.
  • 11. The method of claim 10, wherein the pocket covering is configured to move between a first configuration in which the second portion of the pocket covering has a first length and a second configuration in which the second portion of the pocket covering has a second length smaller than the first length as the prosthetic heart valve transitions from the collapsed delivery condition to the expanded condition.
  • 12. The method of claim 10, wherein the pocket covering, the inner frame, and the outer frame collectively define a pocket in which thrombus can form and be retained when the prosthetic heart valve is in the expanded condition and disposed within the native valve annulus of a patient.
  • 13. The method of claim 12, wherein the pocket closure is formed of a material having a porosity that is sufficiently large to allow red blood cells to pass through the pocket closure into the pocket and that is sufficiently small to prevent thrombus formed from the red blood cells to pass through the pocket closure from the pocket.
  • 14. The method of claim 10, wherein the pocket covering is formed of a shape memory material configured to be to be moved from a biased configuration to an elongated configuration and back to the biased configuration.
  • 15. The method of claim 1, wherein the pocket covering, the inner frame, and the outer frame collectively define a pocket in which thrombus can form and be retained when the prosthetic heart valve is in the expanded condition and disposed within the native valve annulus of a patient.
  • 16. The method of claim 15, wherein the pocket closure is formed of a material having a porosity that is sufficiently large to allow red blood cells to pass through the pocket closure into the pocket and that is sufficiently small to prevent thrombus formed from the red blood cells to pass through the pocket closure from the pocket.
  • 17. The method of claim 1, wherein ejecting the prosthetic heart valve from the delivery device includes ejecting the inner frame from the delivery device after the outer frame is ejected from the delivery device.
  • 18. The method of claim 17, wherein the inner frame retains a same orientation relative to the delivery device as the inner frame is ejected from the delivery device.
  • 19. The method of claim 18, wherein the outer frame reverses orientation relative to the delivery device as the outer frame is ejected from the delivery device.
  • 20. The method of claim 1, wherein delivering the delivery device to the native valve annulus includes passing the delivery device from a right atrium to a left atrium through an atrial septum disposed between the right atrium and the left atrium.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/992,910, filed May 30, 2018, which is a continuation of International Application No. PCT/US2016/068680, filed on Dec. 27, 2016, which claims priority to and the benefit of U.S. Provisional Patent Application No. 62/271,606, entitled “Atrial Pocket Closures for Prosthetic Heart Valves,” filed Dec. 28, 2015, each of the disclosures of which is incorporated herein by reference in its entirety. This application is related to International Application No. PCT/US14/44047, filed Jun. 25, 2014, which is a continuation-in-part of U.S. patent application Ser. No. 14/155,535, filed Jan. 15, 2014, and claims priority to and the benefit of U.S. Provisional Application No. 61/839,237, filed Jun. 25, 2013 and U.S. Provisional Application No. 61/840,313, filed Jun. 27, 2013. The disclosures of the foregoing applications are incorporated herein by reference in their entirety.

US Referenced Citations (764)
Number Name Date Kind
2697008 Ross Dec 1954 A
3409013 Berry Nov 1968 A
3472230 Fogarty et al. Oct 1969 A
3476101 Ross Nov 1969 A
3548417 Kischer Dec 1970 A
3587115 Shiley Jun 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3976079 Samuels et al. Aug 1976 A
4003382 Dyke Jan 1977 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4073438 Meyer Feb 1978 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4470157 Love Sep 1984 A
4490859 Black et al. Jan 1985 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4585705 Broderick et al. Apr 1986 A
4592340 Boyles Jun 1986 A
4605407 Black et al. Aug 1986 A
4612011 Kautzky Sep 1986 A
4626255 Reichart et al. Dec 1986 A
4638886 Marietta Jan 1987 A
4643732 Pietsch et al. Feb 1987 A
4655771 Wallsten Apr 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4759758 Gabbay Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4824180 Levrai Apr 1989 A
4829990 Thuroff et al. May 1989 A
4830117 Capasso May 1989 A
4851001 Faheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4922905 Strecker May 1990 A
4923013 De Gennaro May 1990 A
4960424 Grooters Oct 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
4996873 Takeuchi Mar 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Monso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5064435 Porter Nov 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5192297 Hull Mar 1993 A
5201880 Wright et al. Apr 1993 A
5266073 Wall Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5306296 Wright et al. Apr 1994 A
5332402 Teitelbaum Jul 1994 A
5336616 Livesey et al. Aug 1994 A
5344442 Deac Sep 1994 A
5360444 Kusuhara Nov 1994 A
5364407 Poll Nov 1994 A
5370685 Stevens Dec 1994 A
5397351 Pavcnik et al. Mar 1995 A
5411055 Kane May 1995 A
5411552 Andersen et al. May 1995 A
5415667 Frater May 1995 A
5443446 Shturman Aug 1995 A
5480424 Cox Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545209 Roberts et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554184 Machiraju Sep 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5607462 Imran Mar 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5639274 Fischell et al. Jun 1997 A
5662704 Gross Sep 1997 A
5665115 Cragg Sep 1997 A
5674279 Wright et al. Oct 1997 A
5697905 d'Ambrosio Dec 1997 A
5702368 Stevens et al. Dec 1997 A
5716417 Girard et al. Feb 1998 A
5728068 Leone et al. Mar 1998 A
5728151 Garrison et al. Mar 1998 A
5741333 Frid Apr 1998 A
5749890 Shaknovich May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5792179 Sideris Aug 1998 A
5800508 Goicoechea et al. Sep 1998 A
5833673 Ockuly et al. Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5904697 Gifford, III et al. May 1999 A
5925063 Khosravi Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968052 Sullivan, III et al. Oct 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5972030 Garrison et al. Oct 1999 A
5993481 Marcade et al. Nov 1999 A
6027525 Suh et al. Feb 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6045497 Schweich, Jr. et al. Apr 2000 A
6063112 Sgro May 2000 A
6077214 Mortier et al. Jun 2000 A
6099508 Bousquet Aug 2000 A
6132473 Williams et al. Oct 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6183411 Mortier et al. Feb 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217585 Houser et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6245102 Jayaraman Jun 2001 B1
6260552 Mortier et al. Jul 2001 B1
6261222 Schweich, Jr. et al. Jul 2001 B1
6264602 Mortier et al. Jul 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6332893 Mortier et al. Dec 2001 B1
6350277 Kocur Feb 2002 B1
6358277 Duran Mar 2002 B1
6379372 Dehdashtian et al. Apr 2002 B1
6402679 Mortier et al. Jun 2002 B1
6402680 Mortier et al. Jun 2002 B2
6402781 Langberg et al. Jun 2002 B1
6406420 McCarthy et al. Jun 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6537198 Vidlund et al. Mar 2003 B1
6540782 Snyders Apr 2003 B1
6569196 Vesely May 2003 B1
6575252 Reed Jun 2003 B2
6582462 Andersen et al. Jun 2003 B1
6605112 Moll et al. Aug 2003 B1
6616684 Vidlund et al. Sep 2003 B1
6622730 Ekvall et al. Sep 2003 B2
6629534 St. Goar et al. Oct 2003 B1
6629921 Schweich, Jr. et al. Oct 2003 B1
6648077 Hoffman Nov 2003 B2
6648921 Anderson et al. Nov 2003 B2
6652578 Bailey et al. Nov 2003 B2
6669724 Park et al. Dec 2003 B2
6706065 Langberg et al. Mar 2004 B2
6709456 Langberg et al. Mar 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6726715 Sutherland Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6740105 Yodat et al. May 2004 B2
6746401 Panescu Jun 2004 B2
6746471 Mortier et al. Jun 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6797002 Spence et al. Sep 2004 B2
6810882 Langberg et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6854668 Wancho et al. Feb 2005 B2
6855144 Lesh Feb 2005 B2
6858001 Aboul-Hosn Feb 2005 B1
6890353 Cohn et al. May 2005 B2
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6908424 Mortier et al. Jun 2005 B2
6908481 Cribier Jun 2005 B2
6936067 Buchanan Aug 2005 B2
6945996 Sedransk Sep 2005 B2
6955175 Stevens et al. Oct 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6976543 Fischer Dec 2005 B1
6997950 Chawla Feb 2006 B2
7018406 Seguin et al. Mar 2006 B2
7018408 Bailey et al. Mar 2006 B2
7044905 Vidlund et al. May 2006 B2
7060021 Wilk Jun 2006 B1
7077862 Vidlund et al. Jul 2006 B2
7087064 Hyde Aug 2006 B1
7100614 Stevens et al. Sep 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7108717 Freidberg Sep 2006 B2
7112219 Vidlund et al. Sep 2006 B2
7115141 Menz et al. Oct 2006 B2
7141064 Scott et al. Nov 2006 B2
7175656 Khairkhahan Feb 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7247134 Vidlund et al. Jul 2007 B2
7252682 Seguin Aug 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7275604 Wall Oct 2007 B1
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7316706 Bloom et al. Jan 2008 B2
7318278 Zhang et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7329278 Seguin et al. Feb 2008 B2
7331991 Kheradvar et al. Feb 2008 B2
7335213 Hyde et al. Feb 2008 B1
7374571 Pease et al. May 2008 B2
7377941 Rhee et al. May 2008 B2
7381210 Zarbatany et al. Jun 2008 B2
7381218 Schreck Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7404824 Webler et al. Jul 2008 B1
7416554 Lam et al. Aug 2008 B2
7422072 Dade Sep 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7462191 Spenser et al. Dec 2008 B2
7470285 Nugent et al. Dec 2008 B2
7500989 Solem et al. Mar 2009 B2
7503931 Kowalsky et al. Mar 2009 B2
7510572 Gabbay Mar 2009 B2
7510575 Spenser et al. Mar 2009 B2
7513908 Lattouf Apr 2009 B2
7524330 Berreklouw Apr 2009 B2
7527647 Spence May 2009 B2
7534260 Lattouf May 2009 B2
7556646 Yang et al. Jul 2009 B2
7579381 Dove Aug 2009 B2
7585321 Cribier Sep 2009 B2
7591847 Navia et al. Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7618447 Case et al. Nov 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7632304 Park Dec 2009 B2
7632308 Loulmet Dec 2009 B2
7635386 Gammie Dec 2009 B1
7674222 Nikolic et al. Mar 2010 B2
7674286 Altieri et al. Mar 2010 B2
7695510 Bloom et al. Apr 2010 B2
7708775 Rowe et al. May 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7766961 Patel et al. Aug 2010 B2
7789909 Andersen et al. Sep 2010 B2
7803168 Gifford et al. Sep 2010 B2
7803184 McGuckin, Jr. et al. Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7806928 Rowe et al. Oct 2010 B2
7837727 Goetz et al. Nov 2010 B2
7854762 Speziali et al. Dec 2010 B2
7892281 Seguin et al. Feb 2011 B2
7896915 Guyenot et al. Mar 2011 B2
7901454 Kapadia et al. Mar 2011 B2
7927370 Webler et al. Apr 2011 B2
7931630 Nishtala et al. Apr 2011 B2
7942928 Webler et al. May 2011 B2
7955247 Levine et al. Jun 2011 B2
7955385 Crittenden Jun 2011 B2
7972378 Tabor et al. Jul 2011 B2
7988727 Santamore et al. Aug 2011 B2
7993394 Hariton et al. Aug 2011 B2
8007992 Tian et al. Aug 2011 B2
8029556 Rowe Oct 2011 B2
8043368 Crabtree Oct 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8052750 Tuval et al. Nov 2011 B2
8052751 Aklog et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8062359 Marquez et al. Nov 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8109996 Stacchino et al. Feb 2012 B2
8142495 Hasenkam et al. Mar 2012 B2
8152821 Gambale et al. Apr 2012 B2
8157810 Case et al. Apr 2012 B2
8167932 Bourang et al. May 2012 B2
8167934 Styrc et al. May 2012 B2
8187299 Goldfarb et al. May 2012 B2
8206439 Gomez Duran Jun 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8226711 Mortier et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8241274 Keogh et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8303653 Bonhoeffer et al. Nov 2012 B2
8308796 Lashinski et al. Nov 2012 B2
8323334 Deem et al. Dec 2012 B2
8353955 Styrc et al. Jan 2013 B2
RE44075 Williamson et al. Mar 2013 E
8449599 Chau et al. May 2013 B2
8454656 Tuval Jun 2013 B2
8470028 Thornton et al. Jun 2013 B2
8480730 Maurer et al. Jul 2013 B2
8486138 Vesely Jul 2013 B2
8506623 Wilson et al. Aug 2013 B2
8506624 Vidlund et al. Aug 2013 B2
8578705 Sindano et al. Nov 2013 B2
8579913 Nielsen Nov 2013 B2
8591573 Barone Nov 2013 B2
8591576 Hasenkam et al. Nov 2013 B2
8597347 Maurer et al. Dec 2013 B2
8685086 Navia et al. Apr 2014 B2
8790394 Miller et al. Jul 2014 B2
8845717 Khairkhahan et al. Sep 2014 B2
8888843 Khairkhahan et al. Nov 2014 B2
8900214 Nance et al. Dec 2014 B2
8900295 Migliazza et al. Dec 2014 B2
8926696 Cabiri et al. Jan 2015 B2
8932342 McHugo et al. Jan 2015 B2
8932348 Solem et al. Jan 2015 B2
8945208 Jimenez et al. Feb 2015 B2
8956407 Macoviak et al. Feb 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8986376 Solem Mar 2015 B2
9011522 Annest Apr 2015 B2
9023099 Duffy et al. May 2015 B2
9034032 McLean et al. May 2015 B2
9034033 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
9039759 Alkhatib et al. May 2015 B2
9078749 Lutter et al. Jul 2015 B2
9084676 Chau et al. Jul 2015 B2
9095433 Lutter et al. Aug 2015 B2
9125742 Yoganathan et al. Sep 2015 B2
9149357 Seguin Oct 2015 B2
9161837 Kapadia Oct 2015 B2
9168137 Subramanian et al. Oct 2015 B2
9232995 Kovalsky Jan 2016 B2
9232998 Wilson et al. Jan 2016 B2
9232999 Maurer et al. Jan 2016 B2
9241702 Maisano et al. Jan 2016 B2
9254192 Lutter et al. Feb 2016 B2
9265608 Miller et al. Feb 2016 B2
9289291 Gorman, III Mar 2016 B2
9289295 Aklog et al. Mar 2016 B2
9289297 Wilson et al. Mar 2016 B2
9301836 Buchbinder Apr 2016 B2
9345573 Nyuli et al. May 2016 B2
9480557 Pellegrini et al. Nov 2016 B2
9480559 Vidlund Nov 2016 B2
9526611 Tegels et al. Dec 2016 B2
9532870 Cooper Jan 2017 B2
9597181 Christianson Mar 2017 B2
9610159 Christianson et al. Apr 2017 B2
9675454 Vidlund et al. Jun 2017 B2
9730792 Lutter et al. Aug 2017 B2
9974647 Ganesan May 2018 B2
10390952 Hariton et al. Aug 2019 B2
10610358 Vidlund Apr 2020 B2
11298117 Hariton Apr 2022 B2
11298227 Vidlund Apr 2022 B2
20010018611 Solem et al. Aug 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025171 Mortier et al. Sep 2001 A1
20020010427 Scarfone et al. Jan 2002 A1
20020116054 Lundell et al. Aug 2002 A1
20020139056 Finnell Oct 2002 A1
20020151961 Lashinski et al. Oct 2002 A1
20020161377 Rabkin Oct 2002 A1
20020173842 Buchanan Nov 2002 A1
20030010509 Hoffman Jan 2003 A1
20030036698 Kohler et al. Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030078652 Sutherland Apr 2003 A1
20030100939 Yodat et al. May 2003 A1
20030105519 Fasol et al. Jun 2003 A1
20030105520 Alferness et al. Jun 2003 A1
20030120340 Liska et al. Jun 2003 A1
20030130731 Vidlund et al. Jul 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030212454 Scott et al. Nov 2003 A1
20040039436 Spenser et al. Feb 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040064014 Melvin et al. Apr 2004 A1
20040092858 Wilson et al. May 2004 A1
20040093075 Kuehne May 2004 A1
20040097865 Anderson et al. May 2004 A1
20040127983 Mortier et al. Jul 2004 A1
20040133263 Dusbabek et al. Jul 2004 A1
20040147958 Lam et al. Jul 2004 A1
20040152947 Schroeder et al. Aug 2004 A1
20040162610 Liska et al. Aug 2004 A1
20040163828 Silverstein et al. Aug 2004 A1
20040181239 Dorn et al. Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040260317 Bloom et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20050004652 van der Burg et al. Jan 2005 A1
20050004666 Altieri et al. Jan 2005 A1
20050075727 Wheatley Apr 2005 A1
20050080402 Santamore et al. Apr 2005 A1
20050096498 Houser et al. May 2005 A1
20050107661 Lau et al. May 2005 A1
20050113798 Slater et al. May 2005 A1
20050113810 Houser et al. May 2005 A1
20050113811 Houser et al. May 2005 A1
20050119519 Girard et al. Jun 2005 A9
20050121206 Dolan Jun 2005 A1
20050125012 Houser et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050148815 Mortier et al. Jul 2005 A1
20050177180 Kaganov et al. Aug 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050251209 Saadat et al. Nov 2005 A1
20050256567 Lim et al. Nov 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060004442 Spenser et al. Jan 2006 A1
20060025784 Starksen et al. Feb 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060030885 Hyde Feb 2006 A1
20060042803 Gallaher Mar 2006 A1
20060047338 Jenson et al. Mar 2006 A1
20060052868 Mortier et al. Mar 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060094983 Burbank et al. May 2006 A1
20060129025 Levine et al. Jun 2006 A1
20060142784 Kontos Jun 2006 A1
20060161040 McCarthy et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060167541 Lattouf Jul 2006 A1
20060195134 Crittenden Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060229708 Powell et al. Oct 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060247491 Vidlund et al. Nov 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060282161 Huynh et al. Dec 2006 A1
20060287716 Banbury et al. Dec 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20070005131 Taylor Jan 2007 A1
20070005231 Seguchi Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070016288 Gurskis et al. Jan 2007 A1
20070027535 Purdy et al. Feb 2007 A1
20070038291 Case et al. Feb 2007 A1
20070050020 Spence Mar 2007 A1
20070061010 Hauser et al. Mar 2007 A1
20070066863 Rafiee et al. Mar 2007 A1
20070073387 Forster et al. Mar 2007 A1
20070078297 Rafiee et al. Apr 2007 A1
20070083076 Lichtenstein Apr 2007 A1
20070083259 Bloom et al. Apr 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070100439 Cangialosi et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070112425 Schaller et al. May 2007 A1
20070118151 Davidson May 2007 A1
20070118154 Crabtree May 2007 A1
20070118210 Pinchuk May 2007 A1
20070118213 Loulmet May 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070161846 Nikolic et al. Jul 2007 A1
20070162103 Case et al. Jul 2007 A1
20070168024 Khairkhahan Jul 2007 A1
20070185565 Schwammenthal et al. Aug 2007 A1
20070185571 Kapadia et al. Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070215362 Rodgers Sep 2007 A1
20070221388 Johnson Sep 2007 A1
20070233239 Navia et al. Oct 2007 A1
20070239265 Birdsall Oct 2007 A1
20070256843 Pahila Nov 2007 A1
20070265658 Nelson et al. Nov 2007 A1
20070267202 Mariller Nov 2007 A1
20070270932 Headley et al. Nov 2007 A1
20070270943 Solem et al. Nov 2007 A1
20070293944 Spenser et al. Dec 2007 A1
20080009940 Cribier Jan 2008 A1
20080065011 Marchand et al. Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082163 Woo Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080091264 Machold et al. Apr 2008 A1
20080114442 Mitchell et al. May 2008 A1
20080125861 Webler et al. May 2008 A1
20080147179 Cai et al. Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080172035 Starksen et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080183203 Fitzgerald et al. Jul 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere Aug 2008 A1
20080221672 Lamphere Sep 2008 A1
20080243150 Starksen et al. Oct 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080281411 Berreklouw Nov 2008 A1
20080288060 Kaye et al. Nov 2008 A1
20080293996 Evans et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090048668 Wilson et al. Feb 2009 A1
20090054968 Bonhoeffer et al. Feb 2009 A1
20090054974 McGuckin, Jr. et al. Feb 2009 A1
20090062908 Bonhoeffer et al. Mar 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090082619 De Marchena Mar 2009 A1
20090088836 Bishop et al. Apr 2009 A1
20090099410 De Marchena Apr 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090131849 Maurer et al. May 2009 A1
20090132035 Roth et al. May 2009 A1
20090137861 Goldberg et al. May 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157175 Benichou Jun 2009 A1
20090164005 Dove et al. Jun 2009 A1
20090171432 Von Segesser et al. Jul 2009 A1
20090171447 Von Segesser et al. Jul 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090177266 Powell et al. Jul 2009 A1
20090192601 Rafiee et al. Jul 2009 A1
20090210052 Forster et al. Aug 2009 A1
20090216322 Le et al. Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090224529 Gill Sep 2009 A1
20090234318 Loulmet et al. Sep 2009 A1
20090234435 Johnson et al. Sep 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090248149 Gabbay Oct 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20090326575 Galdonik et al. Dec 2009 A1
20100016958 St. Goar et al. Jan 2010 A1
20100021382 Dorshow et al. Jan 2010 A1
20100023117 Yoganathan et al. Jan 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100161041 Maisano et al. Jun 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100179641 Ryan et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100185278 Schankereli Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100192402 Yamaguchi et al. Aug 2010 A1
20100204781 Mkhatib Aug 2010 A1
20100210899 Schankereli Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249489 Jarvik Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100280604 Zipory et al. Nov 2010 A1
20100286768 Alkhatib Nov 2010 A1
20100298755 McNamara Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110004296 Lutter et al. Jan 2011 A1
20110015616 Straubinger et al. Jan 2011 A1
20110015728 Jimenez et al. Jan 2011 A1
20110015729 Jimenez et al. Jan 2011 A1
20110029072 Gabbay Feb 2011 A1
20110066231 Cartledge et al. Mar 2011 A1
20110066233 Thornton et al. Mar 2011 A1
20110112632 Chau et al. May 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110137408 Bergheim Jun 2011 A1
20110224655 Asirvatham et al. Sep 2011 A1
20110224678 Gabbay Sep 2011 A1
20110224728 Martin et al. Sep 2011 A1
20110224784 Quinn Sep 2011 A1
20110245911 Quill et al. Oct 2011 A1
20110251682 Murray, III et al. Oct 2011 A1
20110264206 Tabor Oct 2011 A1
20110288637 De Marchena Nov 2011 A1
20110319988 Schankereli et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120010694 Lutter et al. Jan 2012 A1
20120016468 Robin et al. Jan 2012 A1
20120022640 Gross et al. Jan 2012 A1
20120035703 Lutter et al. Feb 2012 A1
20120035713 Lutter et al. Feb 2012 A1
20120035722 Tuval Feb 2012 A1
20120059487 Cunanan et al. Mar 2012 A1
20120089171 Hastings et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120116351 Chomas et al. May 2012 A1
20120123529 Levi et al. May 2012 A1
20120165930 Gifford, III et al. Jun 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120203336 Annest Aug 2012 A1
20120215303 Quadri Aug 2012 A1
20120283824 Lutter et al. Nov 2012 A1
20130030522 Rowe et al. Jan 2013 A1
20130053950 Rowe et al. Feb 2013 A1
20130066341 Ketai et al. Mar 2013 A1
20130079873 Migliazza et al. Mar 2013 A1
20130131788 Quadri et al. May 2013 A1
20130172978 Vidlund et al. Jul 2013 A1
20130184811 Rowe Jul 2013 A1
20130190860 Sundt, III Jul 2013 A1
20130190861 Chau Jul 2013 A1
20130197622 Mitra et al. Aug 2013 A1
20130204357 Thill et al. Aug 2013 A1
20130226288 Goldwasser et al. Aug 2013 A1
20130231735 Deem et al. Sep 2013 A1
20130274874 Hammer Oct 2013 A1
20130282101 Eidenschink et al. Oct 2013 A1
20130304200 McLean Nov 2013 A1
20130310928 Morriss Nov 2013 A1
20130317603 McLean et al. Nov 2013 A1
20130325041 Annest et al. Dec 2013 A1
20130325110 Khalil et al. Dec 2013 A1
20130338752 Geusen et al. Dec 2013 A1
20140081323 Hawkins Mar 2014 A1
20140094918 Vishnubholta et al. Apr 2014 A1
20140142691 Pouletty May 2014 A1
20140163668 Rafiee Jun 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140214159 Vidlund et al. Jul 2014 A1
20140222142 Kovalsky Aug 2014 A1
20140243966 Garde et al. Aug 2014 A1
20140249622 Carmi Sep 2014 A1
20140277419 Garde et al. Sep 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140296970 Ekvall et al. Oct 2014 A1
20140296971 Tegels et al. Oct 2014 A1
20140296972 Tegels et al. Oct 2014 A1
20140296975 Tegels et al. Oct 2014 A1
20140303718 Tegels et al. Oct 2014 A1
20140309732 Solem Oct 2014 A1
20140316516 Vidlund et al. Oct 2014 A1
20140324160 Benichou et al. Oct 2014 A1
20140324161 Tegels et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140358224 Tegels et al. Dec 2014 A1
20140364944 Lutter et al. Dec 2014 A1
20140379076 Vidlund et al. Dec 2014 A1
20150005874 Vidlund et al. Jan 2015 A1
20150011821 Gorman et al. Jan 2015 A1
20150025553 Del Nido et al. Jan 2015 A1
20150057705 Vidlund Feb 2015 A1
20150073542 Heldman Mar 2015 A1
20150073545 Braido Mar 2015 A1
20150094802 Buchbinder Apr 2015 A1
20150105856 Rowe et al. Apr 2015 A1
20150119936 Gilmore et al. Apr 2015 A1
20150119978 Tegels et al. Apr 2015 A1
20150127096 Rowe et al. May 2015 A1
20150142100 Morriss May 2015 A1
20150142101 Coleman et al. May 2015 A1
20150142103 Vidlund May 2015 A1
20150142104 Braido May 2015 A1
20150173897 Raanani Jun 2015 A1
20150196393 Vidlund et al. Jul 2015 A1
20150196688 James Jul 2015 A1
20150202044 Chau et al. Jul 2015 A1
20150216653 Freudenthal Aug 2015 A1
20150216660 Pintor Aug 2015 A1
20150223820 Olson Aug 2015 A1
20150238729 Jenson et al. Aug 2015 A1
20150272731 Racchini et al. Oct 2015 A1
20150305860 Wang et al. Oct 2015 A1
20150305864 Quadri Oct 2015 A1
20150305868 Lutter et al. Oct 2015 A1
20150327995 Morin et al. Nov 2015 A1
20150328001 McLean Nov 2015 A1
20150335424 McLean Nov 2015 A1
20150335429 Morriss et al. Nov 2015 A1
20150342717 O'Donnell et al. Dec 2015 A1
20150351903 Morriss Dec 2015 A1
20150351904 Cooper Dec 2015 A1
20150351906 Hammer et al. Dec 2015 A1
20160008131 Christianson et al. Jan 2016 A1
20160067042 Murad et al. Mar 2016 A1
20160074160 Christianson et al. Mar 2016 A1
20160095700 Righini Apr 2016 A1
20160106537 Christianson Apr 2016 A1
20160113764 Sheahan Apr 2016 A1
20160113766 Ganesan Apr 2016 A1
20160143736 Vidlund May 2016 A1
20160151155 Lutter et al. Jun 2016 A1
20160206280 Vidlund et al. Jul 2016 A1
20160242902 Morriss Aug 2016 A1
20160262879 Meiri et al. Sep 2016 A1
20160317290 Chau Nov 2016 A1
20160324635 Vidlund et al. Nov 2016 A1
20160331527 Vidlund et al. Nov 2016 A1
20160346086 Solem Dec 2016 A1
20160367365 Conklin Dec 2016 A1
20160367367 Maisano et al. Dec 2016 A1
20160367368 Vidlund et al. Dec 2016 A1
20170056166 Ratz Mar 2017 A1
20170071733 Ghione Mar 2017 A1
20170079790 Vidlund et al. Mar 2017 A1
20170100248 Tegels et al. Apr 2017 A1
20170128208 Christianson et al. May 2017 A1
20170181854 Christianson et al. Jun 2017 A1
20170196688 Christianson et al. Jul 2017 A1
20170216026 Quill Aug 2017 A1
20170252153 Chau et al. Sep 2017 A1
20170266001 Vidlund et al. Sep 2017 A1
20170312077 Vidlund et al. Nov 2017 A1
20170333187 Hariton et al. Nov 2017 A1
20180014930 Hariton Jan 2018 A1
20180021129 Peterson Jan 2018 A1
20180116798 Perszyk May 2018 A1
20180153687 Hariton Jun 2018 A1
20180206983 Noe Jul 2018 A1
20180271651 Christianson Sep 2018 A1
20180271653 Vidlund et al. Sep 2018 A1
20180296341 Noe Oct 2018 A1
20180325664 Gonda Nov 2018 A1
20190038404 Iamberger et al. Feb 2019 A1
20190038405 Iamberger Feb 2019 A1
20190224008 Bressloff et al. Jul 2019 A1
20190321171 Morriss Oct 2019 A1
20190321178 Tegels Oct 2019 A1
20190343627 Hariton et al. Nov 2019 A1
20200188100 Vidlund Jun 2020 A1
Foreign Referenced Citations (120)
Number Date Country
1486161 Mar 2004 CN
1961845 May 2007 CN
2902226 May 2007 CN
101146484 Mar 2008 CN
101180010 May 2008 CN
101984938 Mar 2011 CN
102869317 Jan 2013 CN
102869318 Jan 2013 CN
102869321 Jan 2013 CN
103220993 Jul 2013 CN
103974674 Aug 2014 CN
102639179 Oct 2014 CN
104188737 Dec 2014 CN
2246526 Mar 1973 DE
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049815 Apr 2002 DE
102006052564 Dec 2007 DE
102006052710 May 2008 DE
102007043831 Apr 2009 DE
0103546 Mar 1984 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
1469797 Nov 2005 EP
2111800 Oct 2009 EP
2193762 Jun 2010 EP
2278944 Feb 2011 EP
2747707 Jul 2014 EP
2918248 Sep 2015 EP
2788217 Jul 2000 FR
2815844 May 2002 FR
2003505146 Feb 2003 JP
2009514628 Apr 2009 JP
1017275 Aug 2002 NL
1271508 Nov 1986 SU
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9829057 Jul 1998 WO
9940964 Aug 1999 WO
9947075 Sep 1999 WO
2000018333 Apr 2000 WO
2000030550 Jun 2000 WO
2000041652 Jul 2000 WO
2000047139 Aug 2000 WO
2001035878 May 2001 WO
200149213 Jul 2001 WO
01 54625 Aug 2001 WO
2001054624 Aug 2001 WO
2001056512 Aug 2001 WO
2001061289 Aug 2001 WO
2001076510 Oct 2001 WO
2001082840 Nov 2001 WO
2002004757 Jan 2002 WO
2002022054 Mar 2002 WO
2002028321 Apr 2002 WO
2002036048 May 2002 WO
2002041789 May 2002 WO
2002043620 Jun 2002 WO
2002049540 Jun 2002 WO
2002076348 Oct 2002 WO
2003003943 Jan 2003 WO
2003030776 Apr 2003 WO
03047468 Jun 2003 WO
2003049619 Jun 2003 WO
2004019825 Mar 2004 WO
2005102181 Nov 2005 WO
2006014233 Feb 2006 WO
2006034008 Mar 2006 WO
2006070372 Jul 2006 WO
2006113906 Oct 2006 WO
2006127756 Nov 2006 WO
2007081412 Jul 2007 WO
2008005405 Jan 2008 WO
2008035337 Mar 2008 WO
2008091515 Jul 2008 WO
2008125906 Oct 2008 WO
2008147964 Dec 2008 WO
2009024859 Feb 2009 WO
2009026563 Feb 2009 WO
2009045338 Apr 2009 WO
2009132187 Oct 2009 WO
2010090878 Aug 2010 WO
2010098857 Sep 2010 WO
2010121076 Oct 2010 WO
2011017440 Feb 2011 WO
2011022658 Feb 2011 WO
2011069048 Jun 2011 WO
2011072084 Jun 2011 WO
2011106735 Sep 2011 WO
2011109813 Sep 2011 WO
2011159342 Dec 2011 WO
2011163275 Dec 2011 WO
2012027487 Mar 2012 WO
2012036742 Mar 2012 WO
2012095116 Jul 2012 WO
2012177942 Dec 2012 WO
2013045262 Apr 2013 WO
2013059747 Apr 2013 WO
2013096411 Jun 2013 WO
2013175468 Nov 2013 WO
2014121280 Aug 2014 WO
2014144937 Sep 2014 WO
2014162306 Oct 2014 WO
2014189974 Nov 2014 WO
2014194178 Dec 2014 WO
2014210124 Dec 2014 WO
2015051430 Apr 2015 WO
2015058039 Apr 2015 WO
2015063580 May 2015 WO
2015065646 May 2015 WO
2015120122 Aug 2015 WO
2015138306 Sep 2015 WO
2016112085 Jul 2016 WO
2016126942 Aug 2016 WO
2016168609 Oct 2016 WO
2016196933 Dec 2016 WO
Non-Patent Literature Citations (52)
Entry
US 9,155,620 B2, 10/2015, Gross et al. (withdrawn)
Chinese Search Report for Appl. No. 201680072656.1 dated Dec. 26, 2019, 2 pages.
Chinese Search Report for Application No. 201680072656.1 dated Nov. 18, 2020,1 page.
Al Zaibag, Muayed, et al., “Percutaneous Balloon Valvotomy in Tricuspid Stenos's,” British Heart Journal, Jan. 1987, vol. 57, No. 1, pp. 51-53.
Al-Khaja, N. et al., “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery, Jun. 30, 1989, 3:305-311.
Almagor, Y. et al., “Balloon Expandable Stent Implantation in Stenotic Right Heart Valved Conduits,” Journal of the American College of Cardiology, Nov. 1, 1990, 16(6):1310-1314.
Andersen, H. R., “History of Percutaneous Aortic Valve Prosthesis,” Herz, Aug. 2009, 34(5):343-346.
Andersen, H. R., “Transluminal catheter implanted prosthetic heart valves,” International Journal of Angiology, 1998, 7(2):102-106.
Benchimol, A. et al., “Simultaneous Left Ventricular Echocardiography and Aortic Blood Velocity During Rapid Right Ventricular Pacing in Man,” The American Journal of the Medical Sciences, Jan.-Feb. 1977, 273(1):55-62.
Boudjemline, Y. et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves: An Experimental Study,” Journal of the American College of Cardiology, Jul. 2005, 46(2):360-365.
Buckberg, G. et al., “Restoring Papillary Muscle Dimensions During Restoration In Dilated Hearts,” Interactive Cardiovascular and Thoracic Surgery, 2005, 4:475-477.
Chamberlain, G., “Ceramics Replace Body Parts,” Design News, Jun. 9, 1997, Issue 11, vol. 52, 5 pages.
Choo, S. J. et al., “Aortic Root Geometry: Pattern of Differences Between Leaflets and Sinuses of Valsava,” The Journal of Heart Valve Disease, Jul. 1999, 8:407-415.
Declaration of Malcolm J. R. Dalrymple-Hay, Nov. 9, 2012, pp. 1-11; with Curriculum Vitae, Oct. 4, 2012.
Dotter, C. T. et al., “Transluminal Treatment of Arteriosclerotic Obstruction. Description of a New Technic and a Preliminary Report of its Application,” Circulation, Nov. 1964, 30:654-670.
Drawbaugh, K., “Feature—Heart Surgeons Explore Minimally Invasive Methods,” Reuters Limited, Jul. 16, 1996, 3 pages.
G. M. Bernacca, et al., “Polyurethane Heart Valves: Fatigue Failure, Calcification, and Polyurethane Structure,” Journal of Biomedical Materials Research, Mar. 5, 1997, Issue 3, vol. 34, pp. 371-379.
Gray, H., The Aorta, Anatomy of the Human Body, 1918, Retrieved from the Internet <http://www.bartleby.com/107/142.html>, Dec. 10, 2012, 5 pages.
Gray, H., The Heart, Anatomy of the Human Body, 1918, Retrieved from the Internet <http://education.yahoo.com/reference/gray/subjects/subject/138>, Aug. 10, 2012, 9 pages.
Greenhalgh, E. S., “Design and characterization of a biomimetic prosthetic aortic heart valve,” 1994, ProQuest Dissertations and Theses, Department of Fiber and Polymer Science, North Carolina State University at Raleigh, 159 pages.
H. R. Andersen et al., “Transluminal Implantation of Artificial Heart Valves. Description of a New Expandable Aortic Valve and Initial Results with Implantation by Catheter Technique in Closed Chest Pigs,” European Heart Journal, 1992, Issue 5, vol. 13, pp. 704-708.
Inoue, K. et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter,” The Journal of Thoracic and Cardiovascular Surgery, 1984, 87:394-402.
Jin, X. Y. et al., “Aortic Root Geometry and Stentless Porcine Valve Competence,” Seminars in Thoracic and Cardiovascular Surgery, Oct. 1999, 11(4):145-150.
Kolata, G., “Device That Opens Clogged Arteries Gets a Failing Grade in a New Study,” New York Times [online], <http://www.nytimes.com/1991/01/03/health/device-that-opens-clogged-arteries-gets-a-faili . . . ,>, published Jan. 3, 1991, retrieved from the Internet on Feb. 5, 2016, 3 pages.
L. L. Knudsen et al., “Catheter-Implanted Prosthetic Heart Valves. Transluminal Catheter Implantation of a New Expandable Artificial Heart Valve in the Descending Thoracic Aorta in Isolated Vessels and Closed Chest Pigs,” International Journal ofArtificial Organs, 1993, Issue 5, vol. 16, pp. 253-262.
Lawrence, D. D., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology, 1987, 163:357-360.
Lozonschi, L., et al. “Transapical mitral valved stent implantation: A survival series in swine,” The Journal of Thoracic and Cardiovascular Surgery, 140(2):422-426 (Aug. 2010) published online Mar. 12, 2010, 1 page.
Lutter, Georg, et al., Mitral valved stent implantation, European Journal of Cardio-Thoracic Surgery, 2010, vol. 38, pp. 350-355.
Ma, L. et al., “Double-crowned valved stents for off-pump mitral valve replacement,” European Journal of Cardio-Thoracic Surgery, Aug. 2005, 28(2): 194-198.
Moazami, N. et al., “Transluminal aortic valve placement: A feasibility study with a newly designed collapsible aortic valve,” ASAIO Journal, Sep./ Oct. 1996, 42(5):M381-M385.
Orton, C., “Mitralseal: Hybrid Transcatheter Mitral Valve Replacement,” Symposium: Small Animal Proceedings, 2011, pp. 311-312.
Pavcnik, M.D., Ph.D., Dusan, et al. “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Radiology, 1992; 183:151-154.
Porstmann, W. et al., “Der Verschluß des Ductus Arteriosus Persistens ohne Thorakotomie,” Thoraxchirurgie Vaskuläre Chirurgie, Band 15, Heft 2, Stuttgart, Apr. 1967, pp. 199-203.
Rashkind, W. J., “Creation of an Atrial Septal Defect Without Thoracotomy,” The Journal of the American Medical Association, Jun. 13, 1966, 196(11): 173-174.
Rashkind, W. J., “Historical Aspects of Interventional Cardiology: Past, Present, Future,” Texas Heart Institute Journal, Dec. 1986, 13(4):363-367.
Reul, H. et al., “The Geometry of the Aortic Root in Health, at Valve Disease and After Valve Replacement,” J. Biomechanics, 1990, 23(2):181-191.
Robert C. Ashton Jr., “Development of an Intraluminal Device for the Treatment of Aortic Regurgitation: Prototype and In Vitro Testing System,” Journal of Thoracic and Cardiovascular Surgery, 1996, Issue/vol. 112, pp. 979-983.
Rosch, J. et al., “The Birth, Early Years and Future of Interventional Radiology,” J Vase Interv Radiol., Jul. 2003, 4:841-853.
Ross, D. N., “Aortic Valve Surgery,” Guys Hospital, London, 1968, pp. 192-197.
Rousseau, E. P. M. et al., “A Mechanical Analysis of the Closed Hancock Heart Valve Prosthesis,” Journal of Biomechanics, 1998, 21(7):545-562.
Sabbah, A. N. et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Dec. 1989, Journal of Cardiac Surgery, 4(4):302-309.
Selby, M.D., J. Bayne, “Experience with New Retrieval Forceps for Foreign Body Removal in the Vascular, Urinary, and Biliary Systems,” Radiology, 1990; 176:535-538.
Serruys, P.W. et al., “Stenting of Coronary Arteries. Are we the Sorcerer's Apprentice?,” European Heart Journal (1989) 10, 774-782, pp. 37-45, Jun. 13, 1989.
Sigwart, U., “An Overview of Intravascular Stents: Old and New,” Chapter 48, Interventional Cardiology, 2nd Edition, W.B. Saunders Company, Philadelphia, PA, © 1994, 1990, pp. 803-815.
Tofeig, M. et al., “Transcatheter Closure of a Mid-Muscular Ventricular Septal Defect with an Amplatzer VSD Occluder Device,” Heart, 1999, 81:438-440.
Uchida, Barry T., et al., “Modifications of Gianturco Expandable Wire Stents,” AJR:150, May 1988, Dec. 3, 1987, pp. 1185-1187.
Watt, A.H. et al., “Intravenous Adenosine in the Treatment of the Supraventricular Tachycardia; a Dose-Ranging Study and Interaction with Dipyridamole,” British Journal of Clinical Pharmacology (1986), 21, pp. 227-230.
Webb, J. G. et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” Circulation, 2006, 113:842-850.
Wheatley, M.D., David J., “Valve Prostheses,” Rob & Smith's Operative Surgery, Fourth Edition, 1986, pp. 415-424, Butterworths 1986.
Yoganathan, A. P. et al., “The Current Status of Prosthetic Heart Valves,” In Polymetric Materials and Artificial Organs, Mar. 20, 1983, pp. 111-150, American Chemical Society.
“Shape Memory Alloys,” Retrieved from the Internet: <http://webdocs.cs.ualberta.ca/˜database/MEMS/sma.html>, Feb. 5, 2016, 3 pages.
International Search Report and Written Opinion for International Application No. PCT/US2016/068680, dated Jun. 16, 2017, 18 pages.
Related Publications (1)
Number Date Country
20200188100 A1 Jun 2020 US
Provisional Applications (1)
Number Date Country
62271606 Dec 2015 US
Continuations (2)
Number Date Country
Parent 15992910 May 2018 US
Child 16797033 US
Parent PCT/US2016/068680 Dec 2016 US
Child 15992910 US